B Group
B Group reported 19 stocks worth $162M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ADMA (20.2%), FTH (11.2%) and PALI (9.5%). Compared with Q2 2026, the fund opened new positions in QTTB, added to NRXP, GPCR and DRUG and trimmed IOVA, SYRE and ORKA.
Latest filing: what B Group did in Q3 2026
vs Q2 2026
QTTB$538K
None
Dollar changes use the share change at the quarter end price. New and sold out show the whole position.
Portfolio at a glance
share of reported value · Q3 2026Holdings
| # | Stock | Value | Weight | Shares | Change | Shares, 8 qtrs | Held |
|---|---|---|---|---|---|---|---|
| 1 | ![]() ADMA Adma Biologics Inc | $32.7M | 20.2% | 3.3M | No change | 8 of 8 | |
| 2 | ![]() FTH Sensei Biotherapeutics Inc | $18.1M | 11.2% | 610K | No change | 2 of 8 | |
| 3 | ![]() PALI Palisade Bio Inc | $15.4M | 9.5% | 11.4M | No change | 4 of 8 | |
| 4 | ![]() NRXP Nrx Pharmaceuticals Inc | $12.5M | 7.7% | 4.3M | +185K (+5%) | 3 of 8 | |
| 5 | ![]() ZLAB Zai Lab Ltd | $11.9M | 7.3% | 451K | No change | 8 of 8 | |
| 6 | ![]() PRAX Praxis Precision Medicines I | $9.7M | 6.0% | 33K | No change | 7 of 8 | |
| 7 | ![]() SGHT Sight Sciences Inc | $9.1M | 5.6% | 970K | No change | 8 of 8 | |
| 8 | ![]() TSHA Taysha Gene Therapies Inc | $8.8M | 5.4% | 1.8M | No change | 8 of 8 | |
| 9 | ![]() IOVA Iovance Biotherapeutics Inc | $6.3M | 3.9% | 425K | −1.1M (−72%) | 8 of 8 | |
| 10 | ![]() GPCR Structure Therapeutics Inc | $5.6M | 3.5% | 180K | +40K (+29%) | 4 of 8 |
Positions at Sep 30, 2026, as reported. Change is against the fund's Q2 2026 filing; weight is the share of the fund's reported stocks.
Reported value
last 8 quartersThe value of the US stocks the fund reported, at quarter end prices. It moves with the market as well as with buying and selling.
Filings for Q3 2026
straight from the SEC| Filed | Form | Quarter | |
|---|---|---|---|
| Nov 16, 2026 | 13F-HR | Q3 2026 | SEC filing ↗ |
Other superinvestors
All hedge fund holdings →B Group 13F FAQ
What does B Group own?
B Group reported 19 stocks worth $162M in its 13F filing for Q3 2026, filed Nov 16, 2026. Its largest holdings are ADMA (20.2%), FTH (11.2%) and PALI (9.5%). The table above lists every position in the filing (the top 10 without an account).
What did B Group buy and sell in Q3 2026?
Compared with Q2 2026: 1 new positions, 3 added to, 3 trimmed and 0 sold out. New positions include QTTB.
When will B Group file its next 13F?
Holdings as of Dec 31, 2026 are due by Feb 15, 2027. The filing appears on this page within minutes of reaching the SEC.
How much is B Group's portfolio worth?
The Q3 2026 filing reports $162M in US stocks. That leaves out cash, bonds, short positions and most foreign holdings, so the fund's total assets are usually larger.
For informational and educational purposes only. Not investment advice, and not a recommendation to buy or sell any security. Holdings come from the fund's SEC Form 13F filings as reported and show positions at the end of the quarter, up to 45 days before the filing. The fund may have changed its positions since. A 13F leaves out short positions, cash, bonds and most foreign holdings. See all hedge fund holdings.












